vs
Side-by-side financial comparison of Dine Brands Global, Inc. (DIN) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Dine Brands Global, Inc. is the larger business by last-quarter revenue ($217.6M vs $177.4M, roughly 1.2× Pacira BioSciences, Inc.). Pacira BioSciences, Inc. runs the higher net margin — 1.6% vs -5.6%, a 7.3% gap on every dollar of revenue. On growth, Dine Brands Global, Inc. posted the faster year-over-year revenue change (6.3% vs 5.0%). Over the past eight quarters, Dine Brands Global, Inc.'s revenue compounded faster (2.7% CAGR vs -0.2%).
Dine Brands Global Inc. is a publicly traded food and beverage company based in Pasadena, California. Founded in 1958 as IHOP, it operates franchised and corporate owned full-service restaurants including three restaurant concepts, Applebee's Neighborhood Grill & Bar, International House of Pancakes (IHOP), and Fuzzy's Taco Shop.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
DIN vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $217.6M | $177.4M |
| Net Profit | $-12.2M | $2.9M |
| Gross Margin | 42.4% | — |
| Operating Margin | -7.6% | 3.9% |
| Net Margin | -5.6% | 1.6% |
| Revenue YoY | 6.3% | 5.0% |
| Net Profit YoY | -336.1% | — |
| EPS (diluted) | $-0.79 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $217.6M | $196.9M | ||
| Q3 25 | $216.2M | $179.5M | ||
| Q2 25 | $230.8M | $181.1M | ||
| Q1 25 | $214.8M | $168.9M | ||
| Q4 24 | $204.8M | $187.3M | ||
| Q3 24 | $195.0M | $168.6M | ||
| Q2 24 | $206.3M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $-12.2M | — | ||
| Q3 25 | $7.3M | $5.4M | ||
| Q2 25 | $13.8M | $-4.8M | ||
| Q1 25 | $8.2M | $4.8M | ||
| Q4 24 | $5.2M | — | ||
| Q3 24 | $19.1M | $-143.5M | ||
| Q2 24 | $23.2M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 42.4% | 79.5% | ||
| Q3 25 | 39.1% | 80.9% | ||
| Q2 25 | 40.0% | 77.4% | ||
| Q1 25 | 42.0% | 79.7% | ||
| Q4 24 | 41.7% | 78.7% | ||
| Q3 24 | 47.8% | 76.9% | ||
| Q2 24 | 48.1% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | -7.6% | 1.2% | ||
| Q3 25 | 4.7% | 3.5% | ||
| Q2 25 | 8.2% | 4.7% | ||
| Q1 25 | 6.0% | 1.2% | ||
| Q4 24 | 3.8% | 13.2% | ||
| Q3 24 | 13.6% | -82.8% | ||
| Q2 24 | 15.1% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | -5.6% | — | ||
| Q3 25 | 3.4% | 3.0% | ||
| Q2 25 | 6.0% | -2.7% | ||
| Q1 25 | 3.8% | 2.8% | ||
| Q4 24 | 2.5% | — | ||
| Q3 24 | 9.8% | -85.1% | ||
| Q2 24 | 11.2% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $-0.79 | $0.05 | ||
| Q3 25 | $0.48 | $0.12 | ||
| Q2 25 | $0.89 | $-0.11 | ||
| Q1 25 | $0.53 | $0.10 | ||
| Q4 24 | $0.35 | $0.38 | ||
| Q3 24 | $1.24 | $-3.11 | ||
| Q2 24 | $1.50 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $128.2M | $144.3M |
| Total DebtLower is stronger | $1.2B | — |
| Stockholders' EquityBook value | $-273.9M | $653.9M |
| Total Assets | $1.7B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $128.2M | $238.4M | ||
| Q3 25 | $167.9M | $246.3M | ||
| Q2 25 | $194.2M | $445.9M | ||
| Q1 25 | $186.5M | $493.6M | ||
| Q4 24 | $186.7M | $484.6M | ||
| Q3 24 | $169.6M | $453.8M | ||
| Q2 24 | $153.5M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $1.2B | $372.2M | ||
| Q3 25 | $1.2B | $376.7M | ||
| Q2 25 | $1.2B | $580.5M | ||
| Q1 25 | $1.2B | $583.4M | ||
| Q4 24 | $1.2B | $585.3M | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $1.2B | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $-273.9M | $693.1M | ||
| Q3 25 | $-231.9M | $727.2M | ||
| Q2 25 | $-212.5M | $757.8M | ||
| Q1 25 | $-215.7M | $798.5M | ||
| Q4 24 | $-216.0M | $778.3M | ||
| Q3 24 | $-216.7M | $749.6M | ||
| Q2 24 | $-231.7M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $1.7B | $1.3B | ||
| Q3 25 | $1.8B | $1.3B | ||
| Q2 25 | $1.8B | $1.5B | ||
| Q1 25 | $1.8B | $1.6B | ||
| Q4 24 | $1.8B | $1.6B | ||
| Q3 24 | $1.7B | $1.5B | ||
| Q2 24 | $1.7B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $5.7M | — |
| Free Cash FlowOCF − Capex | $-8.6M | — |
| FCF MarginFCF / Revenue | -3.9% | — |
| Capex IntensityCapex / Revenue | 6.6% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $53.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $5.7M | $43.7M | ||
| Q3 25 | $30.2M | $60.8M | ||
| Q2 25 | $37.0M | $12.0M | ||
| Q1 25 | $16.1M | $35.5M | ||
| Q4 24 | $30.5M | $33.1M | ||
| Q3 24 | $25.5M | $53.9M | ||
| Q2 24 | $21.6M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $-8.6M | $43.5M | ||
| Q3 25 | $18.1M | $57.0M | ||
| Q2 25 | $31.0M | $9.3M | ||
| Q1 25 | $12.8M | $26.9M | ||
| Q4 24 | $26.7M | $31.0M | ||
| Q3 24 | $22.0M | $49.8M | ||
| Q2 24 | $18.2M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | -3.9% | 22.1% | ||
| Q3 25 | 8.4% | 31.7% | ||
| Q2 25 | 13.4% | 5.1% | ||
| Q1 25 | 6.0% | 15.9% | ||
| Q4 24 | 13.0% | 16.6% | ||
| Q3 24 | 11.3% | 29.6% | ||
| Q2 24 | 8.8% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 6.6% | 0.1% | ||
| Q3 25 | 5.6% | 2.2% | ||
| Q2 25 | 2.6% | 1.5% | ||
| Q1 25 | 1.5% | 5.1% | ||
| Q4 24 | 1.9% | 1.1% | ||
| Q3 24 | 1.8% | 2.4% | ||
| Q2 24 | 1.7% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 4.12× | 11.20× | ||
| Q2 25 | 2.68× | — | ||
| Q1 25 | 1.97× | 7.37× | ||
| Q4 24 | 5.88× | — | ||
| Q3 24 | 1.34× | — | ||
| Q2 24 | 0.93× | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DIN
| Franchisor | $163.2M | 75% |
| Food And Beverage | $27.3M | 13% |
| Proprietary Product Sales And Other | $17.0M | 8% |
| Other | $8.1M | 4% |
| Franchise And Development Fees | $2.0M | 1% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
